Resource Development Core

资源开发核心

• 批准号: 10746903
• 负责人: Salim Hayek
• 金额: $ 27.84万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10746903
• 关键词: Academy; Acute Renal Failure with Renal Papillary Necrosis; Address; Algorithms; Biological; Biological Assay; Biological Markers; Cells; Cessation of life; Characteristics; Chronic Kidney Failure; Clinical; Clinical Trials; Clinical Trials Design; Code; Communities; Core Assembly; Data; Data Analyses; Data Analytics; Data Set; Databases; Development; Diagnosis; Diagnostic; Disease; Education; Educational workshop; Etiology; Feedback; Goals; Health; Healthcare; Incubators; Information Systems; Information Technology; Infrastructure; Kidney; Kidney Diseases; Laboratories; Link; Measures; Medicine; Methods; Michigan; Multiomic Data; National Institute of Diabetes and Digestive and Kidney Diseases; Natural Language Processing; Observational Study; Outcome; Pathway interactions; Patients; Phenotype; Precision Health; Process; Proteomics; Quality Control; Renal function; Research; Research Design; Research Personnel; Resolution; Resource Development; Resources; Sampling; Services; Specificity; Structure; Systems Biology; Technology; Testing; Text; Therapeutic; Training Programs; Training and Education; Translational Research; United States; Universities; Validation; Work; accurate diagnosis; adjudication; annotation system; base; biomarker discovery; candidate marker; candidate selection; clinically relevant; cohort; cost; cost effectiveness; data integration; design; disease phenotype; epigenomics; follow-up; graphical user interface; health data; improved; indexing; innovation; interest; metabolomics; multidimensional data; multidisciplinary; multiple data sources; multiple omics; new technology; novel; novel strategies; pragmatic implementation; pragmatic trial; prognostic; social health determinants; sociodemographics; specific biomarkers; success; technology platform; tool; transcriptomics; trend

ABSTRACT - RESOURCE DEVELOPMENT CORE (RDC) The main goal of the University of Michigan O'Brien Kidney Translational Resource Center (MKTC) is to provide an effective translational research pipeline that relies on a systems biology approach to develop novel, diagnostic, prognostic and therapeutic strategies for patients with kidney diseases. Our Resource Development Core (RDC) will support the Applied Systems Biology Core (ASBC), the Data Analytic Services Core (DASC) and the kidney research community at large by developing a unified platform and methods that integrate multidimensional data, cohort selection and clinical trial design. The University of Michigan Precision Health Initiative (PHI), which incorporates all data from Michigan Medicine patients in addition to social determinants of health and biological samples, represents a unique resource that the RDC will expand upon to develop the following pipelines: a. Biomarker candidate selection, assay, validation, and incorporation into study design. The RDC will establish a database and pipeline to provide investigators the most promising biomarkers, relevant assays based on the outcomes investigated, in addition to guidance surrounding validation and quality control. b. Cohort development. We will leverage the infrastructure of the PHI to build algorithms to identify and curate with high confidence kidney-specific diagnoses, relevant clinical characteristics, laboratory testing, social determinants of health, well as outcomes through integrating multiple data sources including billing codes and natural language processing. The end-result will provide investigators the ability to easily identify relevant cohorts and rapidly retrieve data in a format that is ready to analyze through a graphical user interface. c. Kidney outcomes. We will establish a pipeline to incorporate United States Renal Data System (USRDS) data into the PHI platform, enriching the Michigan Medicine dataset and providing confirmatory data for cohort- specific analyses. d. Novel metabolomic technologies and multi-omic integration. In addition to developing spatial metabolomic platform, we improve tools for annotation of untargeted metabolomics data and identification of new compounds and provide novel integrative analysis of metabolomics-proteomics-transcriptomics- epigenomics data. e. Clinical trial design. We will establish a workflow for kidney-specific clinical trial design and implementation, as well as provide associated workshops through the highly successful Clinical Trials Academy. The pipelines and workflows to be established by the RDC will provide investigators across the spectrum of research stages – from bench (biomarker discovery) to bedside (clinical trial design) – the ability to integrate of multidimensional data – from social determinants of health to organic biomarkers and outcomes – in addressing the major challenges the management of patients with kidney disease.

摘要 - 资源开发核心 (RDC) 密歇根大学奥布莱恩肾脏转化资源中心 (MKTC) 的主要目标是 提供有效的转化研究管道，依赖于系统生物学方法来开发 我们的资源为肾脏疾病患者提供新颖的诊断、预后和治疗策略。 开发核心 (RDC) 将支持应用系统生物学核心 (ASBC)、数据分析服务 Core (DASC) 和整个肾脏研究界通过开发统一的平台和方法， 整合多维数据、队列选择和临床试验设计。 健康倡议 (PHI)，其中包含密歇根医学患者的所有数据以及社交数据 健康和生物样本的决定因素，代表了 RDC 将扩展的独特资源 开发以下管道： a. 生物标志物候选物的选择、测定、验证并纳入研究设计。 建立数据库和管道，为研究人员提供最有前途的生物标志物、相关检测 除了围绕验证和质量控制的指导之外，还基于调查的结果。 b. 我们将利用 PHI 的基础设施来构建算法来识别和管理。 具有高置信度的肾脏特异性诊断、相关临床特征、实验室检测、社会 通过整合多个数据源（包括账单代码和数据）来确定健康的决定因素以及结果 最终结果将使研究人员能够轻松识别相关内容。 群组并以可通过图形用户界面分析的格式快速检索数据。 c. 肾脏结果。我们将建立一个纳入美国肾脏数据系统 (USRDS) 的管道。 数据输入 PHI 平台，丰富了密歇根医学数据集并为队列提供验证性数据 具体分析。 d. 除了空间开发代谢组学之外，新的代谢组学技术和多组学整合。 平台，我们改进了用于注释非目标代谢组学数据和识别新代谢组学数据的工具 化合物并提供代谢组学-蛋白质组学-转录组学-表观基因组学的新型综合分析 数据。 e. 临床试验设计。我们将建立针对肾脏的临床试验设计和实施的工作流程， 以及通过非常成功的临床试验学院提供相关研讨会。 RDC 将建立的管道和工作流程将为各个领域的研究人员提供支持 研究阶段——从实验室（生物标志物发现）到临床（临床试验设计）——整合的能力 多维数据——从健康的社会决定因素到有机生物标志物和结果—— 解决肾脏疾病患者管理的主要挑战。